Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.5%

3 terminated/withdrawn out of 67 trials

Success Rate

94.2%

+7.7% vs industry average

Late-Stage Pipeline

9%

6 trials in Phase 3/4

Results Transparency

61%

30 of 49 completed trials have results

Key Signals

10 recruiting30 with results

Enrollment Performance

Analytics

Phase 1
39(70.9%)
Phase 2
9(16.4%)
Phase 3
4(7.3%)
Phase 4
2(3.6%)
N/A
1(1.8%)
55Total
Phase 1(39)
Phase 2(9)
Phase 3(4)
Phase 4(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (67)

Showing 20 of 67 trials
NCT04807816Phase 2Completed

Targeting ATR in Soft-tissue Sarcomas

Role: collaborator

NCT06589713Phase 1Completed

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Role: lead

NCT06710132Phase 1Recruiting

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Role: collaborator

NCT06577337Phase 1Recruiting

Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants

Role: lead

NCT06308263Phase 1Completed

Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

Role: lead

NCT06806046Phase 1Active Not Recruiting

Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

Role: lead

NCT06463587Phase 3Recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Role: lead

NCT07360314Phase 1Recruiting

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Role: collaborator

NCT05540327Phase 2Active Not Recruiting

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Role: lead

NCT07499362Phase 2Recruiting

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

Role: lead

NCT06641908Phase 1Recruiting

Anti-GD2 ADC M3554 in Advanced Solid Tumors

Role: collaborator

NCT07269327Phase 1Completed

An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin

Role: lead

NCT07340827Phase 3Recruiting

A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)

Role: lead

NCT06412848Active Not Recruiting

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

Role: lead

NCT05797740Active Not Recruiting

Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

Role: lead

NCT05974267Phase 2Completed

Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Role: lead

NCT05248945Phase 1Completed

DDI Study of Evobrutinib and Carbamazepine

Role: lead

NCT05655832Not ApplicableCompleted

A Study to Investigate the Association of Real-world Sensor-derived Biometric Data With Clinical Parameters and Patient-reported Outcomes for Monitoring Disease Activity in Patients With COPD

Role: lead

NCT07214922Phase 1Completed

Relative Bioavailability of Evobrutinib Tablet Batches

Role: lead

NCT05064488Phase 1Completed

Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates

Role: lead